{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T08:05:59Z","timestamp":1784793959474,"version":"3.55.0"},"reference-count":42,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Fundamemntal Clinical Pharma"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cocaine use disorder (CUD) remains a major public health concern, characterized by high relapse rates and the absence of approved pharmacological treatments. Glucagon\u2010like peptide\u20101 receptor agonists (GLP\u20101RA), widely prescribed for metabolic disorders, modulate mesolimbic reward pathways and have been proposed as potential modulators of addictive behaviors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To describe clinical observations of GLP\u20101RA exposure in individuals with CUD identified through the French national vigilance system and to contextualize these findings through a structured narrative review of preclinical and clinical evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cases involving GLP\u20101RA exposure in individuals with ongoing cocaine use were identified through the French national vigilance system and described. A structured literature search (MEDLINE, Embase, Google Scholar) identified original preclinical and clinical studies examining the effects of GLP\u20101 receptor activation on cocaine\u2010related behavioral and neurobiological outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Two cases involving patient\u2010initiated off\u2010label GLP\u20101RA use motivated by perceived anti\u2010craving effects were identified through the vigilance system. The literature synthesis included 22 original publications (17 preclinical and 5 human studies). Across experimental models, GLP\u20101 receptor activation reduced cocaine self\u2010administration, conditioned reward, and relapse\u2010like behaviors. These effects were associated with the attenuation of mesolimbic dopamine signaling, including reduced cocaine\u2010evoked dopamine release and modulation of dopamine transporter function. Human evidence remains limited and heterogeneous.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>GLP\u20101 receptor signaling represents a biologically plausible target in CUD. However, current clinical evidence remains preliminary. Patient\u2010driven observations underscore the need for controlled clinical trials and continued vigilance monitoring<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/fcp.70103","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T04:26:57Z","timestamp":1782880017000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Glucagon\u2010Like Peptide\u20101 Receptor Agonists in Cocaine Use Disorder: Clinical Observations and Underlying Mechanisms"],"prefix":"10.1111","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7839-9811","authenticated-orcid":false,"given":"C\u00e9line","family":"Eiden","sequence":"first","affiliation":[{"name":"Addictovigilance Centre of Montpellier, D\u00e9partement de Pharmacologie M\u00e9dicale et Toxicologie CHU Montpellier  Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghjulia","family":"Chautard","sequence":"additional","affiliation":[{"name":"Addictovigilance Centre of Montpellier, D\u00e9partement de Pharmacologie M\u00e9dicale et Toxicologie CHU Montpellier  Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Batisse","sequence":"additional","affiliation":[{"name":"Addictovigilance Centre of Paris, AP\u2010HP, Nord Universit\u00e9 Paris Cit\u00e9  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Aquizerate","sequence":"additional","affiliation":[{"name":"Addictovigilance Centre of Nantes, Nantes Universit\u00e9, CHU Nantes, Service de Pharmacologie Clinique  Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Luquiens","sequence":"additional","affiliation":[{"name":"Department of Addictology CHU N\u00eemes, Universit\u00e9 Montpellier  N\u00eemes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Donnadieu","sequence":"additional","affiliation":[{"name":"Department of Addictology CHU Montpellier  Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0100-4073","authenticated-orcid":false,"given":"Jean\u2010Luc","family":"Faillie","sequence":"additional","affiliation":[{"name":"Centre de Pharmacovigilance, D\u00e9partement de Pharmacologie M\u00e9dicale et Toxicologie CHU Montpellier  Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4735-9099","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"Peyriere","sequence":"additional","affiliation":[{"name":"Addictovigilance Centre of Montpellier, D\u00e9partement de Pharmacologie M\u00e9dicale et Toxicologie CHU Montpellier  Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"e_1_2_15_2_1","doi-asserted-by":"publisher","DOI":"10.2147\/SAR.S337338"},{"key":"e_1_2_15_3_1","volume-title":"International Standards for the Treatment of Drug Use Disorders: Revised Edition Incorporating Results of Field\u2010Testing","year":"2020"},{"key":"e_1_2_15_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215\u20100366(16)00104\u20108"},{"key":"e_1_2_15_5_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00014.2018"},{"key":"e_1_2_15_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606\u2010019\u201005074\u20108"},{"key":"e_1_2_15_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.8049"},{"key":"e_1_2_15_8_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2006"},{"key":"e_1_2_15_9_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2011\u20101443"},{"key":"e_1_2_15_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15677"},{"key":"e_1_2_15_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1702448"},{"key":"e_1_2_15_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2025.06.001"},{"key":"e_1_2_15_13_1","doi-asserted-by":"publisher","DOI":"10.1017\/neu.2025.10038"},{"key":"e_1_2_15_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41073\u2010019\u20100064\u20108"},{"key":"e_1_2_15_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13256\u2010025\u201005049\u2010w"},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.53941\/cna.2025.100003"},{"key":"e_1_2_15_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2015.362"},{"key":"e_1_2_15_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386\u2010018\u20100010\u20103"},{"key":"e_1_2_15_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2021.113726"},{"key":"e_1_2_15_20_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adr5051"},{"key":"e_1_2_15_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2017.03.019"},{"key":"e_1_2_15_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12583"},{"key":"e_1_2_15_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2021.769664"},{"key":"e_1_2_15_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2025.07.001"},{"key":"e_1_2_15_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2015.47"},{"key":"e_1_2_15_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2016.86"},{"key":"e_1_2_15_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380\u2010020\u201000957\u20103"},{"key":"e_1_2_15_28_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0069010"},{"key":"e_1_2_15_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2015.06.013"},{"key":"e_1_2_15_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.694476"},{"key":"e_1_2_15_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnsys.2021.711750"},{"key":"e_1_2_15_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2012.141"},{"key":"e_1_2_15_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2018.11.001"},{"key":"e_1_2_15_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2017.07.033"},{"key":"e_1_2_15_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108614"},{"key":"e_1_2_15_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001147"},{"key":"e_1_2_15_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16504"},{"key":"e_1_2_15_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.103029"},{"key":"e_1_2_15_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103363"},{"key":"e_1_2_15_40_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.26370"},{"key":"e_1_2_15_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2026.01.011"},{"key":"e_1_2_15_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.4308"},{"key":"e_1_2_15_43_1","unstructured":"ClinicalTrials.gov. Identifier NCT07227948 accessed January 10 2026 https:\/\/clinicaltrials.gov\/study\/NCT07227948."}],"container-title":["Fundamental &amp; Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.70103","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/fcp.70103","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.70103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T07:41:01Z","timestamp":1784792461000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/fcp.70103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1111\/fcp.70103"],"URL":"https:\/\/doi.org\/10.1111\/fcp.70103","archive":["Portico"],"relation":{},"ISSN":["0767-3981","1472-8206"],"issn-type":[{"value":"0767-3981","type":"print"},{"value":"1472-8206","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"2026-03-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70103"}}